Trial Profile
A Randomised, Double-Blind, Multi-Centre, Parallel-Group Phase 3b Study to Demonstrate Non-inferiority of Stavudine (20 mg Twice Daily)Compared With Tenofovir Disoproxil Fumarate (300 mg Once Daily) When Administered in Combination With Lamivudine and Efavirenz in Antiretroviral-Naive Patients Infected With HIV-1
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Stavudine (Primary) ; Efavirenz; Lamivudine; Tenofovir disoproxil fumarate
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- 01 Feb 2019 Results assessing Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine published in the JAIDS
- 31 Oct 2018 Primary endpoint has been met. (Number of participants with undetectable plasma HIV-1 RNA levels)
- 31 Oct 2018 Results presented at the 14th International Congress on Drug Therapy and HIV Infection